- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.05. | OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win | ||
| 22.05. | Biogen axes Denali-partnered Parkinson's prospect after phase 2 flop | ||
| 21.05. | Betting on biotech: Prediction markets set sights on clinical trials | ||
| 21.05. | Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile | ||
| 21.05. | Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI | ||
| 21.05. | Infex, following in Insmed's footsteps, advances lung disease candidate after clearing phase 2a | ||
| 20.05. | Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues | ||
| 20.05. | With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate | ||
| 20.05. | Incyte pays Genesis $80M to expand AI-fueled drug discovery pact | ||
| 20.05. | Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails | ||
| 20.05. | Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug's phase 3 push | ||
| 19.05. | Incyte inks deal with Edison Scientific to train AI through drug discovery | ||
| 19.05. | Merck inks Keytruda supply pact to support Exelixis' colorectal cancer trial | ||
| 19.05. | Relay 'full steam ahead' on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder | ||
| 18.05. | Sanofi and Wave post AATD updates in race to end genetic disease's 40-year new treatment drought | ||
| 18.05. | BioMarin's $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal | ||
| 18.05. | After rare disease flop, cash-strapped Quince finds salvation in reverse merger | ||
| 18.05. | Nominations now open for Fierce Biotech's 2026 Fierce 15 | ||
| 18.05. | Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators | ||
| 18.05. | Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy | ||
| 18.05. | Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3 | ||
| 18.05. | Analysts 'shaking heads' after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial | ||
| 15.05. | Novartis, amid reorg, cuts 'select number' of biomedical research roles | ||
| 15.05. | Alumis pulls back from would-be rival to Amgen's Tepezza after assessing prospects | ||
| 15.05. | Aardvark to dig into phase 3 data early after FDA imposes hold |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.